Immune response to Leishmania infection

Indian Journal of Medical Research

Volumn 119, Issue 6, 2004, Pages 238-258

  Awasthi, Amit ^a   Mathur, Ram Kumar ^a   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Animal models; Antigen presenting cells; Dendritic cells; Host parasite interaction; Immuno modulation; Leishmaniasis; T cell response

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANISOMYCIN; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIMONY GLUCONATE; CD40 LIGAND MONOCLONAL ANTIBODY; CHEMOKINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5; MEGLUMINE ANTIMONATE; NITRIC OXIDE; OKT 4; PENTAMIDINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; STIBOGLUCONATE SODIUM; TUCARESOL; CD28 ANTIGEN;

AMASTIGOTE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CATALYSIS; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DRUG POTENTIATION; GENOTYPE; HOST PARASITE INTERACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION RESISTANCE; INFECTION SENSITIVITY; LEISHMANIA; LEISHMANIASIS; MACROPHAGE ACTIVATION; MAST CELL; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; PARASITE DEVELOPMENT; PARASITE SURVIVAL; REVIEW; STRAIN DIFFERENCE; TH1 CELL; TH2 CELL; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; IMMUNOLOGY; LEISHMANIA DONOVANI; METABOLISM; MONONUCLEAR CELL; MOUSE; PARASITOLOGY; PATHOLOGY; PSYCHODIDAE; SPECIES DIFFERENCE;

ANIMALS; ANTIGENS, CD28; CHEMOKINES; DENDRITIC CELLS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS; LEUKOCYTES, MONONUCLEAR; MAST CELLS; MICE; MODELS, BIOLOGICAL; PSYCHODIDAE; SPECIES SPECIFICITY; TH1 CELLS; TH2 CELLS;

EID: 4043148418     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (205)

1. Killick-Kendrick R. The life-cycle of Leishmania in the sandfly with special reference to the form infective to the vertebrate host. Ann Parasitol Hum Comp 1990; 65 (Suppl) : 37-42.
2. Guevara P, Pinto-Santini D, Rojas A, Crisante G, Anez N, Ramirez JL. Green fluorescent protein-tagged Leishmania in phlebotomine sand flies. J Med Entomol 2001; 38 : 39-43.
3. Hall LR, Titus RG. Sand fly vector saliva selectively modulates macrophage functions that inhibit killing of Leishmania major and nitric oxide production. J Immunol 1995; 155 : 3501-6.
4. Sacks D, Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol 2001; 55 : 453-83.
5. Pulvertaft RJ, Hoyle GF. Stages in the life cycle of Leishmania donovani. Trans R Soc Trop Med Hyg 1960; 54 : 191-6.
6. Carvalho EM, Barral A, Pedral Sampaio D, Barral Netto M, Badaro R, Rocha H, et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 1992; 165 : 535-40.
7. Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165 : 518-27.
8. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002; 8 : 319-42.
9. Bradley DJ. Genetic control of natural resistance to Leishmania donovani. Nature 1974; 250 : 353-4.
10. Howard JG, Hale CE, Chan-Liew WL. Immunological regulation of experimental cutaneous leishmaniasis. I. Immnogenetics aspects of susceptibility to Leishmania tropica in mice. Parasite Immunol 1980; 2 : 303-14.
11. Locksley RM, Heinzel FP, Sadick MD, Holaday BJ, Gardner KD Jr. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T cells subsets. Ann Inst Pasteur Immunol 1987; 138 : 744-9.
12. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A, Lohmann-Matthes ML. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000; 20 : 63-77.
13. Morris L, Troutt AB, McLeod KS, Kelso A, Handman E, Aebischer T. Interleukin-4 but not gamma-interferon production correlates with the severity of murine cutaneous leishmaniasis. Infect Immun 1993; 61 : 3459-65.
14. Himmelrich H, Launois P, Maillard I, Biedermann T, Tacchini-Cottier F, Locksley RM, et al. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol 2000; 164 : 4819-25.
15. Roberts LJ, Baldwin TM, Curtis JM, Handman E, Foote SJ. Resistance to Leishmania major is linked to the H2 region on chromosome 17 and to chromosome 9. J Exp Med 1997; 185 : 1705-10.
16. Beebe AM, Mauze S, Schork NJ, Coffman RL. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity 1997; 6 : 551-7.
17. Saha B, Saini A, Germond R, Perrin PJ, Harlan DM, Davis TA. Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur J Immunol 1999; 29 : 2319-29.
18. Lupasco G, Agavriloaiei A, Ciplea AG. Contribution to the study of the pathogenesis and istopathology of Leishmania donovani infection in the golden hamster (Cricetus auratus). Arch Roum Pathol Exp Microbiol 1961; 20 : 565-78.
19. Gorczynski RM. In vitro analysis of immune responses of inbred guinea pigs infected in vivo with Leishmania enriettii and an investigation of active immunization of susceptible animals. Cell Immunol 1983: 75 : 255-70.
20. Da silva RP, Hall BF, Joiner KA, Sacks DL. CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J Immunol 1989; 143 : 617-22.
21. Wilson ME, Pearson RD. Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. J Immunol 1986; 136 : 4681-8.
22. Guy RA, Belosevic M. Comparison of receptors required for entry of Leishmania major amastigotes into macrophages. Infect Immun 1993; 61 : 1553-8.
23. McConville MJ, Mullin KA, Ilgoutz SC, Teasdale RD. Secretory pathway of trypanosomatid parasites. Microbiol Mol Biol Rev 2002; 66 : 122-54.
24. Beverley SM, Turco SJ. Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmania. Trends Microbiol 1998; 6 : 35-40.
25. Moody SF, Handman E, McConville MJ, Bacic A. The structure of Leishmania major amastigote lipophosphoglycan. J Biol Chem 1993; 268 : 18457-66.
26. Descoteaux A, Turco SJ. Glycoconjugates in Leishmania infectivity. Biochim Biophys Acta 1999: 1455 : 341-52.
27. Mosser DM, Brittingham A. Leishmania, macrophages and complement: a tale of subversion and exploitation. Parasitology 1997; 115 : S9-23.
28. Handman E. Cell biology of Leishmania. Adv Parasitol 1999; 44 : 1-39.
29. Spath GF, Epstein L, Leader B, Singer SM, Avila HA, Turco SJ, et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci USA 2000; 97 : 9258-63.
30. Chaudhuri G, Chang KP. Acid protease activity of a major surface membrane glycoprotein (gp63) from Leishmania mexicana promastigotes. Mol Biochem Parasitol 1988; 27 : 43-52.
31. Chaudhuri G, Chaudhuri M, Pan A, Chang KP. Surface acid proteinase (gp63) of Leishmania mexicana. A metalloenzyme capable of protecting liposome-encapsulated proteins from phagolysosomal degradation by macrophages. J Biol Chem 1989; 264 : 7483-9.
32. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388 : 394-7.
33. Turco SJ, Descoteaux A. The lipophosphoglycan of Leishmania parasites. Annu Rev Microbiol 1992; 46 : 65-94.
34. Antoine JC, Prina E, Jouanne C, Bongrand P. Parasitophorus vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH. Infect Immun 1990; 58 : 779-87.
35. Russell DG, Xu S, Chakraborty P. Intracellular trafficking and the parasitophorus vacuole of Leishmania mexicana-infected macrophages. J Cell Sci 1992; 103 : 1193-210.
36. Antoine JC, Jouanne C, Lang T, Prina E, de Chastellier C, Frehael C. Localization of major histocompatibility complex class II molecules in phagolysosomes of murine macrophages infected with Leishmania amazonensis. Infect Immun 1991; 59 : 764-75.
37. Locksley RM, Reiner SL, Hatam F, Littman DR, Killeen N. Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science 1993; 261 : 1448-51.
38. Wang Z-E, Reiner SL, Hatam F, Heinzel FP, Bouvier J, Truck CW, et al. Targeted activation of CD8 cells and infection of β2-microglobulin-dificient mice fail to confirm a primary protective role of CD8 cells in experimental leishmaniasis. J Immunol 1993; 151 : 2077-86.
39. Woodman RC, Johnston B, Hickey MJ, Tech D, Reinhardt P, Poon BY, et al. The functional paradox of CD43 in leukocyte recruitment: a study using CD43-deficient mice. J Exp Med 1998; 188 : 2181-6.
40. Pearson RD, Steigbigel RT. Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes. J Immunol 1981; 127 : 1438-43.
41. Chang KP. Leishmanicidal mechanisms of human polymorphonuclear phagocytes. Am J Trop Med Hyg 1981; 30 : 322-33.
42. Laufs H, Muller K, Fleischer J, Reiling N, Jahnke N, Jensenius JC, et al. Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heat-labile serum factors. Infect Immun 2002; 70 : 826-35.
43. Sunderkotter C, Kunz M, Steinbrink K, Meinardus-Hager G, Goebeler M, Bildau H, et al. Resistance of mice to experimental leishmaniasis is associated with more rapid appearance of mature macrophages in vitro and in vivo. J Immunol 1993; 151 : 4891-901.
44. Muller K, van Zandbergen G, Hansen B, Laufs H, Jahnke N, Solbach W, et al. Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice. Med Microbiol Immunol (Berl) 2001; 190 : 73-6.
45. Tacchini-Cottier F, Zweifel C, Belkaid Y, Mukankundiye C, Vasei M, Launois P, et al. An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major. J Immunol 2000; 165 : 2628-36.
46. van Zandbergen G, Hermann N, Laufs H, Solbach W, Laskay T. Leishmania promastigotes release a granulocyte chemotactic factor and induce interleukin-8 release but inhibit gamma interferon-inducible protein 10 production by neutrophil granulocytes. Infect Immun 2002; 70 : 4177-84.
47. Squier MK. Apoptosis in leukocytes. J Leukoc Biol 1995; 57 : 2-10.
48. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992; 80 : 2012-20.
49. Aga E, Katschinski DM, van Zandbergen G, Laufs H, Hansen B, Muller K, et al. Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite Leishmania major. J Immunol 2002; 169 : 898-905.
50. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA. The neutrophil as a cellular source of chemokines. Immunol Rev 2000; 177 : 195-203.
51. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83 : 865-75.
52. Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Campbell PA, et al. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol 1992; 149 : 4029-35.
53. Meagher LC, Savill JS, Baker A, Fuller RW, Haslett C. Phagocytosis of apoptotic neutrophils does not induce macrophage release of thromboxane B2. J Leukoc Biol 1992; 52 : 269-73.
54. Laskay T, Zandbergen V, Solbach W. Neutrophil granulocytes-Trojan horses for Leishmania major and other intracellular microbes? Trends Microbiol 2003; 11 : 210-4.
55. Chertov O, Yang D, Howard OM, Oppenheim JJ. Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunol Rev 2000; 177 : 68-78.
56. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol 1999; 73 : 369-509.
57. Lefkowitz DL, Lefkowitz SS. Macrophage-neutrophil interaction: a paradigm for chronic inflammation revisited. Immunol Cell Biol 2001; 79 : 502-6.
58. Kunkel SL, Lukacs N, Strieter RM. Expression and biology of neutrophil and endothelial cell-derived chemokines. Semin Cell Biol 1995; 6 : 327-36.
59. Smelt SC, Cotterell SE, Engwerda CR, Kaye PM. B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J Immunol 2000; 164 : 3681-8.
60. Unanue ER. Perspective on antigen processing and presentation. Immunol Rev 2002; 185 : 86-102.
61. Venuprasad K, Parab P, Prasad DV, Sharma S, Banerjee PP, Deshpande M, et al. Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression. Eur J Immunol 2001; 31 : 1536-43.
62. Venuprasad K, Banerjee PP, Chattopadhyay S, Sharma S, Pal S, Parab PB, et al. Human neutrophil-expressed CD28 interacts with macrophage B7 to induce phosphatidylinositol 3-kinase-dependent IFN-gamma secretion and restriction of Leishmania growth. J Immunol 2002; 169 : 920-8.
63. Venuprasad K, Chattopadhyay S, Saha B. CD28 signaling in neutrophil induces T-cell chemotactic factor(s) modulating T-cell response. Hum Immunol 2003; 64 : 38-43.
64. Ashtekar AR, Saha B. Poly's plea: membership to the club of APCs. Trends Immunol 2003; 24 : 485-90.
65. Ben-Sasson SZ, Le Gros G, Conrad DH, Finkelman FD, Paul WE. Cross linking Fc receptors stimulate splenic non-B, non-T cells to secrete interleukin 4 and other lymphokines. Proc Natl Acad Sci USA 1990; 87 : 1421-5.
66. Seder RA, Paul WE, Dvorak AM, Sharkis SJ, Kagey-Sobotka A, Niv Y, et al. Mouse splenic and bone marrow cell populations that express high-affinity Fce receptors and produce interleukin 4 are highly enriched in basophils. Proc Natl Acad Sci USA 1991; 88 : 2835-9.
67. Galli SJ, Tsai M, Gordon JR, Geissler EN, Wershil BK. Analyzing mast cell development and function using mice carrying mutations at W/c-kit or S1/MGF (SCF) loci. Ann NY Acad Sci 1992; 664 : 69-88.
68. Wershil BK, Theodos CM, Galli SJ, Titus RJ. Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse. J Immunol 1994; 152 : 4563-71.
69. Saha B, Tonkal AMDJ, Croft S, Roy S. Mast cells at the host-pathogen interface: Host-protection versus Immune evasion. Clin Exp Immunol 2004; 137 : 19-23.
70. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20 : 621-67.
71. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184 : 747-52.
72. Qi H, Denning TL, Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun 2003; 71 : 3337-42.
73. Stober D, Schirmbeck R, Reimann J. IL-12/IL-18-dependent IFN-gamma release by murine dendritic cells. J Immunol 2001; 167 : 957-65.
74. Quinones M, Ahuja SK, Melby PC, Pate L, Reddick RL, Ahuja SS. Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. J Exp Med 2000; 192 : 507-16.
75. Kelsall BL, Biron CA, Sharma O, Kaye PM. Dendritic cells at the host-pathogen interface. Nat Immunol 2002; 3 : 699-702.
76. Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998; 28 : 687-95.
77. Sato N, Ahuja SK, Quinones M, Kostecki V, Reddick RL, Melby PC, et al. CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, B cell outgrowth, and sustained neutrophilic inflammation. J Exp Med 2000; 192 : 205-18.
78. Ato M, Stager S, Engwerda CR, Kaye PM. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat Immunol 2002; 3: 1185-91.
79. Scott P, Hunter CA. Dendritic cells and immunity to leishmaniasis and toxoplasmosis. Curr Opin Immunol 2002; 14: 466-70.
80. Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003; 170 : 3171-9.
81. McDowell MA, Marovich M, Lira R, Braun M, Sacks D. Leishmania priming of human dendritic cells for CD40 ligand-induced interleukin-12p70 secretion is strain and species dependent. Infect Immun 2002; 70 : 3994-4001.
82. Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J Immunol 2003; 170 : 5625-9.
83. Shah JA, Darrah PA, Ambrozak DR, Turon TN, Mendez S, Kirman J, et al. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med 2003; 198 : 281-91.
84. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13 : 151-77.
85. Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O'Donnel CA, Liew FY, et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol 1994; 24 : 672-6.
86. Reimann T, Buscher D, Hipskind RA, Krautwald S, Lohmann-Matthes ML, Baccarini M. Lipopolysaccharide induces activation of the Raf-1/MAP kinase pathway. A putative role for Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes. J Immunol 1994; 153 : 5740-9.
87. Hirohashi N, Morrison DC. Low-dose lipopolysaccharide (LPS) pretreatment of mouse macrophages modulates LPS-dependent interleukin-6 production in vitro. Infect Immun 1996; 64 : 1011-5.
88. Kim YM, Im JY, Han SH, Kang HS, Choi I. IFN-gamma up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages. J Immunol 2000; 165 : 3198-205.
89. Kato F, Yamane H, Nariuchi H. Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages. Cell Immunol 1997; 181 : 59-67.
90. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med 1998; 187 : 2103-8.
91. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263 : 235-7.
92. Taylor AP, Murray HW. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med 1997; 185 : 1231-9.
93. Yamane H, Kato T, Nariuchi H. Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells. J Immunol 1999; 162 : 6433-41.
94. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol 1996; 156 : 3932-8.
95. Renard N, Duvert V, Blanchard D, Banchereau J, Saeland S. Activated CD4+ T cells induce CD40-dependent proliferation of human B cell precursors. J Immunol 1994; 152 : 1693-701.
96. Armitage RJ, Maliszewski CR, Alderson MR, Grabstein KH, Spriggs MK, Fanslow WC. CD40L: a multi-functional ligand. Semin Immunol 1993; 5 : 401-12.
97. Soong L, Xu JC, Grewal IS, Kima P, Sun J, Longley, BJ Jr, et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 1996; 4 : 263-73.
98. Awasthi A, Mathur R, Khan A, Joshi BN, Jain N, Sawant S, et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J Exp Med 2003; 197 : 1037-43.
99. Tsuji-Takayama K, Aizawa Y, Okamoto I, Kojima H, Koide K, Takeuchi M, et al. Interleukin-18 induces interferon-gamma production through NF-kappaB and NFAT activation in murine T helper type 1 cells. Cell Immunol 1999; 196 : 41-50.
100. Wei XQ, Leung BP, Niedbala W, Piedrafita D, Feng GJ, Sweet M, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999; 163 : 2821-8.
101. Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM, Esteban M. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003; 5 : 73-84.
102. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to the Th2 pathway in interferon γ -deficient mice infected with Leishmania major. J Exp Med 1994; 179 : 1367-71.
103. Swihart K, Fruth U, Messmer N, Hug K, Behin R, Huang S, et al. Mice from a genetically resistant background lacking the interferon γ receptor are susceptible to infection with Leishmania major but mount a polarized Th1 CD4+ T cell response. J Exp Med 1995; 181 : 961-71.
104. Scott P, Pearce E, Cheever AW, Coffman RL, Sher A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989; 112 : 161-82.
105. Bogdan C, Gessner A, Rollinghoff M. Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology 1993; 189 : 356-96.
106. Liew FY, O'Donnell CA. Immunology of leishmaniasis. Adv Parasitol 1993; 32 : 161-259.
107. Green SJ, Nacy CA, Meltzer MS. Cytokine-induced synthesis of nitrogen oxide in macrophages: a protective host response to Leishmania and other intracellular pathogens. J Leukoc Biol 1991; 50 : 93-103.
108. Green SJ, Meltzer MS, Hibbs JB, Nacy CA. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 1990; 144 : 278-86.
109. Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990; 144 : 4794-7.
110. Evans TG, Thai L, Granger DL, Hibbs JB. Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. J Immunol 1993; 151 : 907-15.
111. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart T. Multiple defects in immune cell function in mice with disrupted interferon γ-genes. Science 1993; 259 : 1739-42.
112. Kamijo R, Shapiro D, Le JM, Huang S, Aguet M, Vilcek J. Generation of nitric oxide and induction of major histocompatibility complex class II antigen in macrophages from mice lacking the interferon-γ receptor. Proc Natl Acad Sci USA 1993; 90 : 6626-30.
113. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988; 141 : 2407-12.
114. Moll H, Binoder K, Bogdan C, Solwach W, Rollinghoff M. Production of tumor necrosis factor during murine cutaneous leishmaniasis. Parasite Immunol 1990; 12 : 483-94.
115. De Kossodo S, Grau GE, Louis JA, Muller I. Tumor necrosis factor alpha (TNF-α) and TNF-β and their receptors in experimental cutaneous leishmaniasis. Infect Immunol 1994; 62 : 1414-20.
116. Green SJ, Crawford RM, Hockmeyer JT, Meltzer MS, Nacy CA. Leishmania major amastigote initiates the L-arginine dependent killing mechanism in IFN-γ stimulated macrophages by induction of TNF-α. J Immunol 1990; 145 : 4290-7.
117. Deng W, Thiel B, Tannenbaum CS, Hamilton TA, Stuehr DJ. Synergistic cooperation between T cell lynphokines for induction of the nitric oxide synthase gene in murine peritoneal macrophages. J Immunol 1993; 151 : 322-9.
118. Titus RG, Sherry B, Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989: 170 : 2097-104.
119. Liew FY, Parkinson C, Millott S, Severn A, Carrier M. Tumor necrosis factor alpha (TNF-α) in leishmaniasis. I. TNF-α mediates host protection against cutaneous leishmaniasis. Immunology 1990; 69 : 570-3.
120. Belosevic M, Finbloom DS, Meltzer MS, Nacy CA. IL-2. A cofactor for induction of activated macrophage resistance to infection. J Immunol 1990; 145 : 831-9.
121. Bogdan C, Stenger S, Rollinghoff M, Solbach W. Cytokine intractions in experimental cutaneous leishmaniasis. Interleukine-4 synergizes with interferon-γ to activate murine macrophages for killing Leishmania major amastigotes. Eur J Immunol 1991; 21 : 327-33.
122. Gessner A, Veith M, Will A, Schroppel K, Rollinghoff M. Interleukine-7 enhances antimicrobial activity against Leishmania major in murine macrophages. Infect Immun 1993; 61 : 4008-12.
123. Liew FY, Millott S, Li Y, Lelchuk R, Chan WL, Ziltener H. Macrophage activation by interferon-γ from host protective T cell is inhibited by interleukin (IL) 3 and IL 4 produced by disease promoting T cells in leishmaniasis. Eur J Immunol 1989; 19 : 1227-32.
124. Leal LMCC, Moss DW, Kuhn R, Muller W, Liew FY. Interleukin-4 transgenic mice of resistant background are susceptible to Leishmania major infection. Eur J Immunol 1993; 23 : 566-9.
125. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169 : 59-72.
126. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with anti interleukin 4 monoclonal antibody. J Exp Med 1990; 171 : 115-27.
127. Stahl N, Yancopoulos GD. The alphas, betas and kinases of cytokine receptor complexes. Cell 1993; 74 : 587-90.
128. Feng YF, Louis J, Kindler V, Pedrrazini T, Eliason JF, Behin R, et al. Aggravation of experimental cutaneous leishmaniasis in mice by administration of interleukin 3. Eur J Immunol 1988; 18 : 1245-5.
129. Greil J, Bodendorfer B, Rollinghoff M, Solwach W. Application of recombinant granulocyte-macrophage colony stimulating factor has a detrimental effect in experimental murine leishmaniasis. Eur J Immunol 1988; 18 : 1527-33.
130. Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun 1993; 61 : 220-6.
131. LeClerc C, Modabber F, Deriaud E, Chedid L. Systemic infection of Leishmania tropica (major) in various strains of mice. Trans R Soc Trop Med Hyg 1981; 75 : 851-4.
132. Antoine JC, Lang T, Prina E, Courret N, Hellio R. H-2M molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of Leishmania-infected macrophages and internalized by amastigotes of L. amazonensis and L. mexicana. J Cell Sci 1999; 112 : 2559-70.
133. Kima PE, Soong L, Chicharro C, Ruddle NH, McMahon-Pratt D. Leishmania-infected macrophages sequester endogenously synthesized parasite antigens from presentation to CD4+ T cells. Eur J Immunol 1996; 26 : 3163-9.
134. Meier CL, Svensson M, Kaye PM. Leishmania-induced inhibition of macrophage antigen presentation analyzed at the single-cell level. J Immunol 2003; 171 : 6706-13.
135. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11 : 211-6.
136. Saha B, Das G, Vohra H, Ganguly NK, Mishra GC. Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. Eur J Immunol 1995; 25 : 2492-8.
137. Nandan D, Yi T, Lopez M, Lai C, Reiner NE. Leishmania EF-1alpha activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J Biol Chem 2002; 277 : 50190-7.
138. Forget G, Siminovitch KA, Brochu S, Rivest S, Radzioch D, Olivier M. Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis. Eur J Immunol 2001; 31 : 3185-96.
139. Holaday BJ, Sadick MD, Wang ZE, Reiner SL, Heinzel FP, Parslow PG, et al. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. J Immunol 1991; 147 : 1653-8.
140. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity to exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168 : 1675-84.
141. Moll H, Scollay R, Mitchell GF. Resistance to cutaneous leishmaniasis in nude mice injected with L3T4+ T cells but not with L-2+ T cells. Immunol Cell Biol 1988; 66 : 57-63.
142. Scott P, Caspar P, Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 1990; 144 : 1075-9.
143. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168 : 1675-84.
144. Lopez JA, Reins HA, Etges RJ, Button LL, McMaster WR, Overath P, et al. Genetic control of immune response in mice to Leishmania mexicana surface protease. J Immunol 1991; 146 : 1328-34.
145. Jardim A, Alexander J, Teh HS, Ou D, Olafson RW. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med 1990; 172 : 645-8.
146. Murray PJ, Handman E, Glacer TA, Spithill TW. Leishmania major : expression and gene structure of the glyco-protein 63 molecule in virulent and avirulent clones and strains. Exp Parasitol 1990; 71 : 294-304.
147. Reiner SL, Wang ZE, Hatam F, Scott P, Locksley RM. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 1993; 259 : 1457-60.
148. Launois P, Maillard I, Pingel S, Swihart KG, Xenarios I, Acha-Orbea H, et al. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997; 6 : 541-9.
149. Lohoff M, Steinert M, Weiss A, Rollinghoff M, Balderas RS, Theofilopoulos AN. V beta gene repertoires in T cells expanded in local self-healing and lethal systemic murine cutaneous leishmaniasis. Eur J Immunol 1994; 24 : 492-5.
150. + T cells. Annu Rev Immunol 1994; 12 : 635-73.
151. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukin 4 and 10 in an αβ T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89 : 6065-9.
152. Seder RA, Paul WE, Davis MM, Fazekas de St. Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992; 176 : 1091-8.
153. +T cells through IL-12 produced by Listeria induced macrophages. Science 1993; 260 : 547-9.
154. + T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-g dependent. Int Immunol 1993; 5 : 1119-28.
155. Tanaka T, Hu Li J, Seder RA, Fazekas de st Groth B, Paul WE. Interleukin 4 suppresses interleukin 2 and interferon γ production by naïve T cells stimulated by accessory cell-dependent receptor engagement. Proc Natl Acad Sci USA 1993; 90 : 5914-8.
156. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993; 90 : 10188-92.
157. + T cells during initiation of infection. J Exp Med 1994; 179 : 447-56.
158. Locksley RM, Reiner SL, Hatam F, Littman DR, Killeen N. Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science 1993; 261 : 1448-51.
159. Fowell DJ, Magram J, Turck CW, Killeen N, Locksley RM. Impaired Th2 subset development in the absence of CD4. Immunity 1997; 6 : 559-69.
160. Uzonna JE, Bretscher PA. Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice. Eur J Immunol 2001; 31 : 3175-84.
161. Kopf M, Brombacher F, Kohler G, Kienzle G, Widmann KH, Lefrang K, et al. IL-4-deficient BALB/c mice resist infection with Leishmania major. J Exp Med 1996; 184 : 1127-36.
162. Heinzel FP, Rerko RM, Hatam F, Locksley RM. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 1993; 150 : 3924-31.
163. Ben-Sasson SZ, Le Gros G, Conrad DH, Finkelman FD, Paul WE. IL-4 production by T cells from naive donors. IL-2 is required for IL-4 production. J Immunol 1990; 145 : 1127-36.
164. Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 1996; 271 : 987-90.
165. Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001; 2 : 1054-60.
166. + cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol 2003; 171 : 2270-8.
167. Boehler A. The role of interleukin-10 in lung transplantation. Transpl Immunol 2002; 19 : 121-4.
168. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166 : 1141-7.
169. Reed SG, Brownell CE, Russo DM, Silva JS, Grabstein KH, Morrissey PJ. IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol 1994; 153 : 3135-40.
170. Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 2003; 170 : 5152-8.
171. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31 : 2848-56.
172. Padigel UM, Alexander J, Farrell JP. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 2003; 171 : 3705-10.
173. Viana da Costa A, Huerre M, Delacre M, Auriault C, Correia Costa JM, Verwaerde C. IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. Parasitol Int 2002; 51 : 367-79.
174. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194 : 1497-506.
175. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G, et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002; 70 : 6284-93.
176. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31 : 2848-56.
177. Yamakami K, Akao S, Tadakuma T, Nitta Y, Miyazaki J, Yoshizawa N. Administration of plasmids expressing interleukin-4 and interleukin-10 causes BALB/c mice to induce a T helper 2-type response despite the expected T helper 1-type response with a low-dose infection of Leishmania major. Immunology 2002; 105 : 515-23.
178. Scott P. IFN-γ modulates the early development of Th1 & Th2 response in murine model of cutaneous leishmaniasis. J Immunol 1991; 147 : 3149-55.
179. Tobin JF, Reiner SL, Hatam F, Zheng S, Leptak C, Wirth DF, et al. Transfected Leishmania expressing biological IFN-γ. J Immunol 1993; 150 : 5059-69.
180. Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 1989; 143 : 266-74.
181. Kirkpatrick CE, Farrel JP. Leishmaniasis in beigh mice. Infect Immun 1982; 38 : 1208-16.
182. Scharton TM, Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993; 178 : 567-77.
183. Laskay T, Rollinghoff M, Solbach W. Natural killer cells participates in the early defense against Leishmania major infection in mice. Eur J Immunol 1993; 23 : 2237-41.
184. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995; 154 : 5320-30.
185. Laskay T, Diefenbach A, Rollinghoff M, Solbach W. Early parasite containment is decisive for resistance to Leishmania major infection. Eur J Immunol 1995; 25 : 2220-7.
186. Rosat JP, MacDonald R, Louis JA. A role of γ/δ + T cells during experimental infection of mice with Leishmania major. J Immunol 1993; 150 : 550-5.
187. Serbina NV, Flynn JL. CD8 (+) T cells participate in the memory immune response to Mycobacterium tuberculosis. Infect Immun 2001; 69 : 4320-8.
188. Muller I, Kropf P, Etges RJ, Louis JA. Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun 1993; 6 : 3730-8.
189. Stefani MM, Muller I, Louis JA. Leishmania major-specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrophages. Eur J Immunol 1994; 24 : 746-52.
190. Erb K, Blank C, Ritter U, Bluethmann H, Moll H. Leishmania major infection in major histocompatibility complex class II-deficient mice: CD8+ T cells do not mediate a protective immune response. Immunobiology 1996; 195 : 243-60.
191. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, Bertholet S, et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002; 168 : 3992-4000.
192. Colmenares M, Kima PE, Samoff E, Soong L, McMahon-Pratt D. Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun 2003; 71 : 3172-82.
193. Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R, et al. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996; 183 : 515-26.
194. Hondowicz BD, Scharton-Kersten TM, Jones DE, Scott P. Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response. J Immunol 1997; 159 : 5024-31.
195. Park AY, Hondowicz BD, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 2000; 165 : 896-902.
196. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996; 26 : 1553-9.
197. Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis 1997; 175 : 1477-9.
198. Himmelrich H, Parra-Lopez C, Tacchini-Cottier F, Louis JA, Launois P. The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor beta 2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12. J Immunol 1998; 161 : 156-63.
199. Launois P, Swihart KG, Milon G, Louis JA. Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness. J Immunol 1997; 158 : 3317-24.
200. Szabo SJ, Kim. ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100 : 655-69.
201. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89 : 587-96.
202. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19 : 502-8.
203. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmanissa donovani. J Infect Dis 1999; 180 : 564-7.
204. Smith AC, Yardley V, Rhodes J, Croft SL. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2000; 44: 1494-8.
205. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B. Reciprocal CD40 signals through p38 MAPK and ERK-1/2 induce counteracting immume responses. Nat Med 2004; 10 : 540-4.